Discover
ASND
Ascendis Pharma A/S
219.88
2 x 158.76
2 x 282.34
bid
ask
+
3.09
1.43%
02:00 PM
timesize
| Ytd | 3.11% | |
| 1y | 26.59% |
217.48
day range
222.81
160.86
52 week range
250.74
| Open | 219.93 | Prev Close | 216.79 | Low | 217.48 | High | 222.81 | Mkt Cap | 13.58B |
| Vol | 277.92K | Avg Vol | 634.83K | EPS | 8.80 | P/E | 24.99 | Forward P/E | 19.71 |
| Beta | 0.48 | Short Ratio | 2.10 | Inst. Own | 110.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 232.77 | 200-d Avg | 216.47 | 1yr Est | 298.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0.21 | 0.32 | 0.11 | 52.38% |
| 2026-02-11 | 2025-12 | 0 | N/A | -0.58 | -966.67% |
| 2025-11-12 | 2025-09 | 0 | N/A | -0.76 | -185.37% |
| 2025-08-07 | 2025-06 | 0 | N/A | 0.49 | 34.51% |
| 2025-05-01 | 2025-03 | 0 | N/A | -0.1 | -6.41% |
| 2025-02-12 | 2024-12 | 0 | N/A | 0.52 | 43.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-19 | Citigroup | Upgrade | Buy | |
| 2026-05-15 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-11 | Barclays | Upgrade | Overweight | Overweight |
| 2026-05-08 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-04-16 | B of A Securities | Upgrade | Buy | Buy |
| 2026-04-09 | Wedbush | Upgrade | Outperform | Outperform |
Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-28 | BIENAIME JEAN-JACQUES | Director | 900.00 | Purchase |
| 2026-05-10 | JENSEN FLEMMING STEEN | Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SBI Securities Co., Ltd. | 3.00 | 649.00 | 0.00% |
| 2026-03-30 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 5.78K | 1.25M | 0.00% |
| 2026-03-30 | Legato Capital Management LLC | 1.75K | 378.18K | 0.00% |
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 6.16M | 1.33B | 0.00% |
| 2026-03-30 | Price (T.Rowe) Associates Inc | 1.53M | 331.09M | 0.00% |
| 2026-03-30 | Driehaus Capital Management, LLC | 127.56K | 27.60M | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | First Trust Exchange-Traded Fund III-First Trust Long/Short Equity ETF | 15.59K | 3.37M | 0.00% |
| 2026-04-29 | AdvisorShares Trust-AdvisorShares Dorsey Wright ADR ETF | 5.59K | 1.21M | 0.00% |
| 2026-04-29 | Invesco Exchange-Traded Fund Trust II-Invesco Nasdaq Biotechnology ETF | 3.27K | 707.68K | 0.00% |
| 2026-04-29 | First TRT Exch-Trd Fd. VIII-First TRT Innovation Leaders ETF | 13.80K | 2.99M | 0.00% |
| 2026-04-29 | SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 60.53K | 13.10M | 0.00% |
| 2026-04-29 | Manager Directed Portfolios-Spyglass Growth Fund | 163.67K | 35.41M | 0.00% |
